Dr. Rosenberg Discusses the Importance of Clinical Trials in Bladder Cancer

Jonathan E. Rosenberg, MD
Published: Wednesday, Sep 06, 2017



Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.

There is a long history of failed adjuvant clinical trials in bladder cancer due to poor accrual, says Rosenberg. He says that is important for treating physicians to recommend patients for these trials in order to test novel adjuvant therapies.

Adjuvant immunotherapy trials are showing greater success in accrual though, Rosenberg adds.
 


Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.

There is a long history of failed adjuvant clinical trials in bladder cancer due to poor accrual, says Rosenberg. He says that is important for treating physicians to recommend patients for these trials in order to test novel adjuvant therapies.

Adjuvant immunotherapy trials are showing greater success in accrual though, Rosenberg adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x